AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Transplant Clinic

Font Size:

AlloMap Testing Description

	Genes & Pathways
	The AlloMap Testing Process
	XDx Reference Laboratory

Developing AlloMap Testing

Billing & Reimbursement

Existing customers: click here to order supplies.

The AlloMap Testing Process

From Ordering Tests to Delivering Results

AlloMap molecular expression testing is conducted only at the XDx Reference Laboratory in Brisbane, California. Transplant centers must draw and prepare the blood sample according to the specifications outlined in the XDx Reference Laboratory Services Guide and send it to the XDx Reference Laboratory. XDx provides all equipment and supplies and conducts on-site training for sample preparation.

This diagram illustrates the typical AlloMap testing process. Place your mouse over each numbered section for more details. After testing is complete, in most circumstances, XDx bills the patient’s insurer directly. Click here for more information on billing and reimbursement.

AlloMap testing process